Germany to recognise Bharat Biotech's COVAXIN for travel from June 1
Wednesday, February 8, 2023
  • Circulation
  • Advertise
  • About Us
  • Contact Us
Organiser
  • ‌
  • Bharat
  • World
  • G20
  • Editorial
  • Analysis
  • Opinion
  • Sports
  • More
    • Defence
    • RSS in News
    • Azadi Ka Amrit Mahotsav
    • My States
    • Vocal4Local
    • Business
    • Special Report
    • Culture
    • Sci & Tech
    • Entertainment
    • Education
    • Books
    • Interviews
    • Travel
    • Health
    • Obituary
SUBSCRIBE
No Result
View All Result
  • ‌
  • Bharat
  • World
  • G20
  • Editorial
  • Analysis
  • Opinion
  • Sports
  • More
    • Defence
    • RSS in News
    • Azadi Ka Amrit Mahotsav
    • My States
    • Vocal4Local
    • Business
    • Special Report
    • Culture
    • Sci & Tech
    • Entertainment
    • Education
    • Books
    • Interviews
    • Travel
    • Health
    • Obituary
No Result
View All Result
Organiser
No Result
View All Result
  • Home
  • Bharat
  • World
  • G20
  • Editorial
  • Opinion
  • Analysis
  • Culture
  • Defence
  • RSS in News
  • My States
  • Vocal4Local
  • Subscribe
Home World

Germany to recognise Bharat Biotech’s COVAXIN for travel from June 1

German Ambassador to India, Walter J Lindner said the German government for recognising the WHO-listed Bharat Biotech's COVID vaccine, COVAXIN, for travel to the country starting June 1.

WEB DESK by WEB DESK
May 26, 2022, 11:55 am IST
in World
COVAXIN

COVAXIN

Share on FacebookShare on TwitterTelegramEmail

New Delhi [India]: German Ambassador to India, Walter J Lindner, on Thursday (May 26) hailed the German government for recognising the WHO-listed Bharat Biotech’s COVID vaccine, COVAXIN, for travel to the country starting June 1.

In November last year, World Health Organization (WHO) issued an emergency use listing (EUL) for COVAXIN, adding to a growing portfolio of vaccines validated for the prevention of COVID-19 caused by SARS-CoV-2.

Taking to Twitter, the Ambassador to Germany and Bhutan Lindner wrote, “Very happy that GER government just decided to recognise WHO-listed Covaxin for travels to GER, starting June 1! This Embassy has been pushing very actively for such decision (because of Covid-backlogs visa sections have longer waiting periods than normal, please have patience).”

Very happy that GER government just decided to recognize WHO-listed Covaxin for travels to GER, starting June 1! This Embassy has been pushing very actively for such decision (because of Covid-backlogs visa sections have longer waiting periods than normal, please have patience) pic.twitter.com/LFKqlyYzaW

— Walter J. Lindner (@WalterJLindner) May 26, 2022

WHO’s EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines and is a prerequisite for COVAX vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

“This emergency use listing expands the availability of vaccines, the most effective medical tools we have to end the pandemic,” said Dr Mariangela Simao, WHO Assistant-Director General for Access to Medicines and Health Products said.

In April, the Drugs Controller General of India (DCGI) also granted an emergency use authorisation (EUA) to Covaxin for the age group of 6-12 years.

In a statement, the Hyderabad-based Pharma company Bharat Biotech said that it had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity of Covaxin in healthy children and adolescents in the 2-18 age group.

The clinical trials conducted in the paediatric population between June 2021 to September 2021 have shown robust safety, reactogenicity, and immunogenicity.

Covaxin is formulated uniquely such that the same dosage can be administered to adults and children alike. Covaxin is a ready-to-use liquid vaccine, stored at 2-8 degrees Celsius, with 12 months shelf life and a multi-dose vial policy.

Moreover, Biotechnology company Ocugen on Monday announced that the US Food and Drug Administration (FDA) lifted the clinical hold on the Company’s Phase 2 and 3 clinical trials for COVAXIN (BBV152).

Chairman, CEO, and Co-Founder of Ocugen Inc., Dr Shankar Musunuri, said, “We’re extremely pleased that we can proceed with our clinical trials for COVAXIN, our whole virus inactivated COVID-19 vaccine candidate. The need for delivering an additional, differentiated vaccine option, we believe, remains a priority.” (ANI)

 

 

Topics: COVAXINBharat BiotechWHOIndiaGermany
Share1TweetSendShareSend
Previous News

ED raids multiple locations in Maharashtra linked to Shiv Sena minister Anil Parab in money laundering case

Next News

Pakistan on the boil as Imran Khan’s ‘march to chaos’ continues

Related News

Turkey Earthquake: India to send two more IAF planes with rescue personnel, relief materials

Turkey Earthquake: India to send two more IAF planes with rescue personnel, relief materials

India joins hands with France, UAE in trilateral defence, energy cooperation

India joins hands with France, UAE in trilateral defence, energy cooperation

US, India see each other as ‘trusted partners’, says Indian Envoy

US, India see each other as ‘trusted partners’, says Indian Envoy

Russia supports India becoming permanent member of UNSC, says ambassador

Russia supports India becoming permanent member of UNSC, says ambassador

The Normalisation Phenomena: Strategic desperation of neighbours amid New Delhi’s rise

The Normalisation Phenomena: Strategic desperation of neighbours amid New Delhi’s rise

Rana Ayyub Money Laundering Case: Apex Court reserves order on Ayyub’s plea against summons issued by Ghaziabad court

Rana Ayyub Money Laundering Case: Apex Court reserves order on Ayyub’s plea against summons issued by Ghaziabad court

Comments

The comments posted here/below/in the given space are not on behalf of Organiser. The person posting the comment will be in sole ownership of its responsibility. According to the central government's IT rules, obscene or offensive statement made against a person, religion, community or nation is a punishable offense, and legal action would be taken against people who indulge in such activities.

Latest News

Civilian killings dropped from 37 to 30 in Jammu & Kashmir: Modi Government in Lok Sabha

Civilian killings dropped from 37 to 30 in Jammu & Kashmir: Modi Government in Lok Sabha

BJP leader sues Kerala Pradesh Congress Committee president, CPM MLA for blaming RSS for Gandhi’s assassination

BJP leader sues Kerala Pradesh Congress Committee president, CPM MLA for blaming RSS for Gandhi’s assassination

In fridge, nullah, dustbin, jungle, Shamshan Ghat: Gory details emerge in Shraddha murder case

In fridge, nullah, dustbin, jungle, Shamshan Ghat: Gory details emerge in Shraddha murder case

Maharashtra: Pastor among four arrested for raping a Hindu woman; forced her and family to convert to Christianity

Maharashtra: Pastor among four arrested for raping a Hindu woman; forced her and family to convert to Christianity

Salman Rushdie appeares for the first time after knife attack by Islamist in August 2022; lost vision in one eye

Salman Rushdie appeares for the first time after knife attack by Islamist in August 2022; lost vision in one eye

Kerala: CPM goons try to disrupt RSS Shakha in Malappuram

Kerala: CPM goons try to disrupt RSS Shakha in Malappuram

Under-19 Women’s T20 World Cup: How India’s daughters created History

Under-19 Women’s T20 World Cup: How India’s daughters created History

Budget 2023: Special attention towards rural economy to create employment opportunities

Budget 2023: Special attention towards rural economy to create employment opportunities

Kerala: Eyewitness to the brutal murder of  BJYM State Vice President KT Jayakrishnan Master, ends her life

Kerala: Eyewitness to the brutal murder of BJYM State Vice President KT Jayakrishnan Master, ends her life

Indian shuttler Tanya Hemanth forced to wear hijab in Tehran – Here are details

Indian shuttler Tanya Hemanth forced to wear hijab in Tehran – Here are details

  • Privacy
  • Terms
  • Cookie Policy
  • Refund and Cancellation
  • Delivery and Shipping

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies

No Result
View All Result
  • Home
  • Bharat
  • World
  • Editorial
  • Analysis
  • Opinion
  • Defence
  • Culture
  • Sports
  • Business
  • RSS in News
  • My States
  • Vocal4Local
  • Special Report
  • Sci & Tech
  • Entertainment
  • Education
  • Books
  • Interviews
  • Travel
  • Health
  • Obituary
  • Subscribe
  • Advertise
  • Circulation
  • About Us
  • Contact Us
  • Privacy Policy
  • Cookie Policy
  • Terms of Use
  • Refund and Cancellation

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies